Nanobiotix S.A. NBTX Open Nanobiotix S.A. in new tab
Nanobiotix S.A. Analysis (NBTX)
Is Nanobiotix S.A. a good investment? Nanobiotix S.A. (NBTX) is currently trading at 49.48 USD. Market analysts have a consensus price target of 33.76 USD. This suggests the asset is currently trading above analyst expectations.
Earnings Schedule: Nanobiotix S.A. is expected to release its next earnings report on May 19, 2026. The market consensus estimate for Forward EPS is 0.15.
Investor FAQ
Does Nanobiotix S.A. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Nanobiotix S.A.?
Nanobiotix S.A. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be May 19, 2026. The company currently has a trailing EPS of -0.59.
Company Profile
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Dividends
Historical Split Corporate Actions
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion